The Jack L. Beal Award is bestowed upon younger investigators, persons within 12 years of receiving their Ph.D. degree or within 10 years of gaining their first professional appointment. The award is named after a former editor of the Journal of Natural Product. All Beal Award winning papers can be accessed via the Journal of Natural Products website at http://pubs.acs.org/journal/jnprdf. The Journal publishes papers that make substantial and scholarly contributions to the area of natural products research. Contributions relate to the chemistry and/or biochemistry of naturally occurring compounds or the biology of living systems from which they are obtained. It is co-published with The American Society of Pharmacognosy.
Based in Catalent’s Trade Place facility in San Diego, CA, part of the organization’s Respiratory, Analytical and Biotechnology group, Dr. Westenburg works to structurally identify impurities for virtual, generic, small-, and mid-size pharmaceutical companies. In his current capacity, he has been able to identify impurities belonging to a large number of structural classes. The identification of these impurities supports the client to enable greater reporting thresholds or, in some instances, identify an impurity causing discoloration of a drug substance or product. During the past two years, Dr. Westenburg has routinely monitored low-level genotoxic impurities by QTOF LCMS in a drug product. For the past decade, the majority of his work has been in the impurity identification for pharmaceutical companies concerning impurities in drug substances [Q3A(R2)] and impurities in drug products [Q3B(R2)], in compliance with the International Conference on Harmonization (ICH) guidelines.
About Catalent
Headquartered in Somerset, New Jersey, Catalent Pharma Solutions is a leading provider of advanced dose form and packaging technologies, and development, manufacturing and packaging services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes. Catalent employs approximately 9,100 at more than 30 facilities worldwide and in fiscal 2008 generated more than $1.8 billion of annual revenue. For more information, visit http://www.catalent.com.
